Matching articles for "Oxecta"

Extended-Release Oxycodone and Acetaminophen (Xartemis XR)

   
The Medical Letter on Drugs and Therapeutics • July 21, 2014;  (Issue 1447)
The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen (Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is...
The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen (Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is available in the US as a single entity in oral immediate-release (Oxecta, and others) and extendedrelease (OxyContin) formulations. Immediate-release oxycodone is also available in combination with aspirin (Percodan, and others), acetaminophen (Percocet, and others), or ibuprofen (see Table 1).
Med Lett Drugs Ther. 2014 Jul 21;56(1447):59-61 | Show Full IntroductionHide Full Introduction

Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • April 1, 2013;  (Issue 128)
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Treat Guidel Med Lett. 2013 Apr;11(128):31-42 | Show Full IntroductionHide Full Introduction

In Brief: Immediate-Release Oxycodone (Oxecta) for Pain

   
The Medical Letter on Drugs and Therapeutics • March 5, 2012;  (Issue 1385)
The FDA has approved a new tablet formulation of immediate-release (IR) oxycodone (Oxecta – King) for management of acute and chronic moderate to severe pain.Oxecta uses a tamper-resistant technology designed...
The FDA has approved a new tablet formulation of immediate-release (IR) oxycodone (Oxecta – King) for management of acute and chronic moderate to severe pain.

Oxecta uses a tamper-resistant technology designed to deter oxycodone abuse by injection or nasal snorting. Dissolving the crushed tablet in water or alcohol converts it into a viscous gel mixture, making it difficult to inject. Crushing the tablet and inhaling it through the nose causes burning and irritation. Whether the new formulation will actually prevent abuse of the drug has not been established. Oxecta is classified as a Schedule II controlled substance.1

In patients who have not been receiving opioid analgesics, the recommended starting dosage of Oxecta is 5 to 15 mg every 4 to 6 hours as needed for pain. Oxycodone has no analgesic ceiling, but dosage is usually limited by its adverse effects. Use of similar abuse-resistant tablets has been associated with reports of difficulty swallowing the tablets.2 Oxecta tablets should be swallowed whole and taken with enough water to ensure complete swallowing.

1. Drugs for pain.Treat Guidel Med Lett 2010; 8:25.

2. US Food and Drug Administration. Center for Drug Evaluation and Research. Oxecta (oxycodone HCl) tablets. Summary Review. Available at www.accessdata.fda.gov/scripts/cder/drugsatfda. Acccessed February 24, 2012.

Download complete U.S. English article

Med Lett Drugs Ther. 2012 Mar 5;54(1385):20 | Show Full IntroductionHide Full Introduction